PROFILPELAJAR.COM

Lucid-MS

Lucid-MS
Clinical data
Other namesLucid-21-302
Routes of
administration		Oral[1][2]
Drug classProtein arginine deiminase 2 (PAD2) inhibitor
ATC code
  • None
Pharmacokinetic data
Elimination half-life1.5–2.5 hours[2]

Lucid-MS, also known as Lucid-21-302, is a protein arginine deiminase 2 (PAD2) inhibitor which is under development for the treatment of multiple sclerosis.[1][3][4][2] It is taken orally.[1][2]

The drug is described as a non-immunomodulatory neuroprotective agent against demyelination and is said to be a potential first-in-class medication.[1][4][2] The pharmacokinetics of Lucid-MS have been described.[4][2]

It was originated by University Health Network and has been developed by FSD Pharma, Lucid Psycheceuticals, and Quantum Biopharma.[1][3][4] As of February 2026, Lucid-MS is in phase 1 clinical trials, with at least one phase 1 trial having been completed and published.[1][3][4][2] A phase 2 trial is being planned.[4] The chemical structure of Lucid-MS does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f g "Lucid MS". AdisInsight. Springer Nature Switzerland AG. 16 March 2025. Retrieved 27 March 2026.
  2. ^ a b c d e f g Chruscinski A, Joshi A, Stys P, Antel J, Kotra L (February 2026). P131 / P131 - Results of a Phase 1 Multiple Ascending Dose Trial of Lucid-21-302 (Lucid-MS) in Healthy Volunteers: A Novel Myelin Protective Small Molecule to Prevent Disease Progression in Multiple Sclerosis. 2026 ACTRIMS Forum. San Diego, CA. Abstract P131.
  3. ^ a b c "Delving into the Latest Updates on Lucid 21 302 with Synapse". Synapse. 13 December 2025. Retrieved 27 March 2026.
  4. ^ a b c d e f Meglio M (27 March 2026). "Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers". NeurologyLive. Retrieved 27 March 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.